Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $90.50M), while Vanguard Real Estate Index Fund ETF trades at $98.98. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | VNQ | |
|---|---|---|
Market Cap | $90.50M | — |
Sector | Health | — |
52-Week High | $2.87 | $100.07 |
52-Week Low | $1.05 | $87.00 |
Enterprise Value | $61.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
VNQ trades at $99.50, down 0.52% today, with technical indicators showing a bullish moving average trend but neutral oscillators. The ETF holds a dominant position in U.S. real estate with a low expense ratio of 0.13% (The Motley Fool, 2026-07-18). Recent news highlights strong year-to-date performance and comparisons with competing REIT ETFs.
Outlook remains positive due to sector momentum and income appeal, though risks include interest rate sensitivity and potential overvaluation signals from RSI levels. The dividend schedule provides income stability, but macroeconomic factors could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
